MedTrace Logo

Effects of Donepezil on Deficits Associated With Age-Related Decrease of Growth Hormone

NCT00533065 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2009-08-07

No results posted yet for this study

Summary

The planned study has two purposes:

1. It is to provide evidence that the administration of a cholinesterase inhibitor will result in an increase of IGF-I (primary variable) and in an increase of the secretion growth hormone (secondary variable) that can be maintained throughout the treatment-period of one year.
2. The study also tests the hypothesis that maintenance of increased blood levels of growth hormone and IGF-I can stop or delay the age-related changes of body composition (secondary variables) .

Conditions

  • Elderly

Interventions

DRUG

Donepezil

week1 - week12: 1 tablet per day (5mg) week13 - week52: 1 tablet per day (10mg)

Sponsors & Collaborators

  • Ludwig Boltzmann Gesellschaft

    lead OTHER

Principal Investigators

  • Karl H Tragl, MD · Ludwig Boltzmann Institute of Aging Research

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
70 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00533065 on ClinicalTrials.gov